Shots:                                                                                                              

• The US FDA has granted Dermia’s Lebrikizumab Fast Track Designation an investigational drug targeted to treat moderate-to-severe atopic dermatitis
• The Fast Track Designation is granted to facilitate the drug development process and expedite the review of therapies treating serious conditions and demonstrating an advantage over currently available therapy
• Lebrikizumab is a mAb designed to bind to IL-13 further preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling currently evaluated in two P-III trial for- ADvocate 1 and Advocate 2 confirming safety- efficacy- in adolescent and adult patients- ages 12 years and older- with moderate-to-severe atopic dermatitis

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance